Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista brasileira de hematologia e hemoterapia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000600428 |
Resumo: | In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major cause of death; however, hepatic and endocrine complications also occur. Currently there are three iron chelating agents available for continuous use in patients with thalassemia on regular transfusions (desferrioxamine, deferiprone, and deferasirox) providing good results in reducing cardiac, hepatic and endocrine toxicity. These practice guidelines, prepared by the Scientific Committee of Associação Brasileira de Thalassemia (ABRASTA), presents a review of the literature regarding iron overload assessment (by imaging and laboratory exams) and the role of T2* magnetic resonance imaging (MRI) to control iron overload and iron chelation therapy, with evidence-based recommendations for each clinical situation. Based on this review, the authors propose an iron chelation protocol for patients with thalassemia under regular transfusions. |
id |
ABHHTC-1_fcab0f70e9b2cf48f4f5d14bf30ebd7b |
---|---|
oai_identifier_str |
oai:scielo:S1516-84842013000600428 |
network_acronym_str |
ABHHTC-1 |
network_name_str |
Revista brasileira de hematologia e hemoterapia (Online) |
repository_id_str |
|
spelling |
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusionBlood transfusionChelation therapyDeferiproneDeferasiroxIron/metabolismbeta-ThalassemiaIron overloadIron chelating agentsMagnetic resonance imagingPractice guidelines as topicProtocolsBrazilIn the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major cause of death; however, hepatic and endocrine complications also occur. Currently there are three iron chelating agents available for continuous use in patients with thalassemia on regular transfusions (desferrioxamine, deferiprone, and deferasirox) providing good results in reducing cardiac, hepatic and endocrine toxicity. These practice guidelines, prepared by the Scientific Committee of Associação Brasileira de Thalassemia (ABRASTA), presents a review of the literature regarding iron overload assessment (by imaging and laboratory exams) and the role of T2* magnetic resonance imaging (MRI) to control iron overload and iron chelation therapy, with evidence-based recommendations for each clinical situation. Based on this review, the authors propose an iron chelation protocol for patients with thalassemia under regular transfusions.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2013-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000600428Revista Brasileira de Hematologia e Hemoterapia v.35 n.6 2013reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.5581/1516-8484.20130106info:eu-repo/semantics/openAccessVerissimo,Monica Pinheiro de AlmeidaLoggetto,Sandra ReginaFabron Junior,AntonioBaldanzi,Giorgio RobertoHamerschlak,NelsonFernandes,Juliano LaraAraujo,Aderson da SilvaLobo,Clarisse Lopes de CastroFertrin,Kleber YotsumotoBerdoukas,Vasilios AntoniosGalanello,Renzoeng2014-01-29T00:00:00Zoai:scielo:S1516-84842013000600428Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2014-01-29T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false |
dc.title.none.fl_str_mv |
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion |
title |
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion |
spellingShingle |
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion Verissimo,Monica Pinheiro de Almeida Blood transfusion Chelation therapy Deferiprone Deferasirox Iron/metabolism beta-Thalassemia Iron overload Iron chelating agents Magnetic resonance imaging Practice guidelines as topic Protocols Brazil |
title_short |
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion |
title_full |
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion |
title_fullStr |
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion |
title_full_unstemmed |
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion |
title_sort |
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion |
author |
Verissimo,Monica Pinheiro de Almeida |
author_facet |
Verissimo,Monica Pinheiro de Almeida Loggetto,Sandra Regina Fabron Junior,Antonio Baldanzi,Giorgio Roberto Hamerschlak,Nelson Fernandes,Juliano Lara Araujo,Aderson da Silva Lobo,Clarisse Lopes de Castro Fertrin,Kleber Yotsumoto Berdoukas,Vasilios Antonios Galanello,Renzo |
author_role |
author |
author2 |
Loggetto,Sandra Regina Fabron Junior,Antonio Baldanzi,Giorgio Roberto Hamerschlak,Nelson Fernandes,Juliano Lara Araujo,Aderson da Silva Lobo,Clarisse Lopes de Castro Fertrin,Kleber Yotsumoto Berdoukas,Vasilios Antonios Galanello,Renzo |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Verissimo,Monica Pinheiro de Almeida Loggetto,Sandra Regina Fabron Junior,Antonio Baldanzi,Giorgio Roberto Hamerschlak,Nelson Fernandes,Juliano Lara Araujo,Aderson da Silva Lobo,Clarisse Lopes de Castro Fertrin,Kleber Yotsumoto Berdoukas,Vasilios Antonios Galanello,Renzo |
dc.subject.por.fl_str_mv |
Blood transfusion Chelation therapy Deferiprone Deferasirox Iron/metabolism beta-Thalassemia Iron overload Iron chelating agents Magnetic resonance imaging Practice guidelines as topic Protocols Brazil |
topic |
Blood transfusion Chelation therapy Deferiprone Deferasirox Iron/metabolism beta-Thalassemia Iron overload Iron chelating agents Magnetic resonance imaging Practice guidelines as topic Protocols Brazil |
description |
In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major cause of death; however, hepatic and endocrine complications also occur. Currently there are three iron chelating agents available for continuous use in patients with thalassemia on regular transfusions (desferrioxamine, deferiprone, and deferasirox) providing good results in reducing cardiac, hepatic and endocrine toxicity. These practice guidelines, prepared by the Scientific Committee of Associação Brasileira de Thalassemia (ABRASTA), presents a review of the literature regarding iron overload assessment (by imaging and laboratory exams) and the role of T2* magnetic resonance imaging (MRI) to control iron overload and iron chelation therapy, with evidence-based recommendations for each clinical situation. Based on this review, the authors propose an iron chelation protocol for patients with thalassemia under regular transfusions. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000600428 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000600428 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.5581/1516-8484.20130106 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
dc.source.none.fl_str_mv |
Revista Brasileira de Hematologia e Hemoterapia v.35 n.6 2013 reponame:Revista brasileira de hematologia e hemoterapia (Online) instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) instacron:ABHHTC |
instname_str |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
instacron_str |
ABHHTC |
institution |
ABHHTC |
reponame_str |
Revista brasileira de hematologia e hemoterapia (Online) |
collection |
Revista brasileira de hematologia e hemoterapia (Online) |
repository.name.fl_str_mv |
Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
repository.mail.fl_str_mv |
sbhh@terra.com.br||secretaria@rbhh.org |
_version_ |
1754213112028856320 |